Anti-Obesity Medications Help Normalize Testosterone Levels in Men
New research shows that anti-obesity medications can significantly increase testosterone levels in men with obesity or type 2 diabetes, improving reproductive health and overall well-being.
Recent research presented at ENDO 2025, the annual meeting of the Endocrine Society in San Francisco, highlights that anti-obesity medications such as semaglutide, dulaglutide, and tirzepatide may play a significant role in increasing testosterone levels in men suffering from obesity or type 2 diabetes. The study analyzed the electronic health records of 110 men who were treated with these weight-loss drugs over an 18-month period, without concurrent testosterone therapy. Results showed that, alongside an average weight loss of 10%, the percentage of men with normal total and free testosterone levels increased from 53% to 77%. This suggests that these medications do not only aid in weight reduction and blood sugar control but also have a positive impact on male reproductive health. Testosterone is vital for numerous bodily functions, including maintaining muscle mass, bone density, red blood cell production, and sexual health. Lower levels of testosterone are often linked to obesity and metabolic disorders, leading to symptoms such as fatigue, decreased libido, and reduced quality of life. While lifestyle changes and bariatric surgery are known to boost testosterone, this new evidence indicates that pharmacological intervention can also reverse testosterone deficiency. This discovery opens new avenues for treating men with obesity and low testosterone, emphasizing the importance of considering anti-obesity medications as part of comprehensive health management.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Parents Support Early HPV Vaccination for Children at Age 9 or 10
A new study reveals that most parents and clinicians are receptive to administering the HPV vaccine to children at ages 9 or 10, potentially improving vaccination rates and cancer prevention efforts.
New Research Uncovers How Tirzepatide and Semaglutide Differ in Their Metabolic Effects
Animal studies reveal that tirzepatide temporarily increases energy expenditure, while semaglutide initially decreases it, offering new insights into obesity treatment mechanisms.
Link Between Missing Y Chromosome Gene and Male Infertility Uncovered
Scientists at the University of Hawaiʻi at Mānoa have discovered that the absence of a specific Y chromosome gene, Zfy, causes male infertility by disrupting gene regulation and sperm development. This research provides valuable insights into the genetic causes of reproductive issues in men.
New Guidelines for Managing Grade 4 Diffuse Glioma
Updated clinical guidelines for managing grade 4 diffuse glioma emphasize targeted radiation therapy, chemotherapy, and personalized treatment approaches to improve patient outcomes.